(Stockholm, 8 December 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences Sweden AB (ISAB), has received an order worth 55 752 Euros for a new research project from Italian pharma company Chiesi. The joint research project is between Chiesi and the Institute of Environmental Medicine (IMM) at Karolinska Institutet (KI). Both Chiesi and IMM, leading research bodies within inhalation, are returning ISAB customers.

The IRS study is valued at 55 752 Euros. It will be carried out at IMM's research facilities at Karolinska Insittutet in Stockholm under the leadership of KI's Professor Lena Palmberg, a long-term ISAB collaborator.

The study will use XposeALI®, ISAB's highly innovative in vitro cell culturing tool that combines the aerosol capability from PreciseInhale® with cell exposures at an Air Liquid Interface that mimic closely the physiologic processes as they happen in the lungs.

2021 has seen significant events around XposeALI®: in October it was chosen to test a Mars dust surrogate for the European Space Agency in another IMM research project. In the same month its US patent was extended. In November the module received its US Registered Trademark, together with ISAB's core aerosol generating system PreciseInhale® and in vitro dissolution module DissolvIt®.

CEO Manoush Masarrat: "Both Chiesi and KI are recognized worldwide as leading bodies in inhalation research. It is a powerful endorsement of our technology that they choose us time and again to achieve their early stage results. We are delighted too to see them recognize the unique capabilities and benefits of XposeALI®. We believe it will become a recognized leader within its niche."

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on December 8, 2021.

https://news.cision.com/inhalation-sciences/r/inhalation-research-services-receives-order-for-new-joint-research-project-between-chiesi-and-karoli,c3467906

https://mb.cision.com/Main/15842/3467906/1507013.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English